A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of VX-548 for Acute Pain
Sponsor: Vertex Pharmaceuticals Incorporated
Listed as NCT05661734, this PHASE3 trial focuses on Pain and remains completed. Sponsored by Vertex Pharmaceuticals Incorporated, it has been updated 17 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE3
-
Jan 2025 — Aug 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 12 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE3
-
May 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Vertex Pharmaceuticals Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .